Impromen

Bromperidol, the active ingredient in Impromen, is a butyrophenone antipsychotic presented as an oral formulation for oral use. It acts by blocking dopamine D2 receptors and is indicated for the treatment of schizophrenia and acute psychotic episodes in adult patients.

GNH USA supplies Impromen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for this EU‑origin antipsychotic medication. The company adheres to stringent quality standards and offers global logistics to ensure product integrity throughout the supply chain.

Bromperidol is a butyrophenone antipsychotic that modulates dopaminergic pathways in psychotic disorders.

- Schizophrenia: Reduces positive and negative symptoms, helping stabilize mood and thought processes. - Acute psychotic episodes: Controls severe agitation and hallucinations, facilitating rapid symptom control. - Psychotic disorders (e.g., schizoaffective disorder): Assists in managing psychotic features when other therapies are insufficient.

Bromperidol may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: Excessive sleepiness or fatigue. - Extrapyramidal symptoms: Muscle stiffness, tremor, or restlessness. - Dry mouth: Reduced salivation causing discomfort. - Constipation: Decreased bowel movements. - Weight gain: Increase in body weight over time. - Orthostatic hypotension: Dizziness upon standing due to blood pressure drop.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Persistent involuntary movements, especially of the face. - Cardiac arrhythmias: Irregular heart rhythm that may require monitoring. - Seizures: Rare occurrence of convulsive episodes. - Severe hypotension: Marked drop in blood pressure that can lead to fainting.

When prescribing bromperidol, clinicians should consider several safety precautions to minimize risks. - Assess cardiac history: Evaluate for pre‑existing arrhythmias or QT prolongation. - Monitor for extrapyramidal signs: Observe patients for early signs of movement disorders. - Review metabolic status: Check for diabetes or lipid abnormalities that may be worsened. - Caution in elderly: Increased susceptibility to sedation and falls. - Avoid abrupt discontinuation: Taper dose to prevent withdrawal or rebound psychosis. - Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture.

Bromperidol can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - CYP2D6 inhibitors: Potent inhibitors (e.g., fluoxetine, paroxetine) may increase bromperidol plasma levels. - QT‑prolonging agents: Co‑administration with other QT‑prolonging drugs (e.g., haloperidol, quinidine) raises risk of arrhythmia. - CNS depressants: Combined use with benzodiazepines or opioids can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: May worsen dry mouth and constipation. - Antihypertensives: Additive orthostatic hypotension effects. - Lithium: Potential for increased neurotoxicity; monitor serum levels.